-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Update
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Update
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 1,930,000 shares, a drop of 18.2% from the July 15th total of 2,360,000 shares. Based on an average daily volume of 335,800 shares, the short-interest ratio is currently 5.7 days.
Kiniksa Pharmaceuticals Trading Up 2.1 %
NASDAQ KNSA traded up $0.25 during trading hours on Friday, hitting $12.41. 404,852 shares of the company's stock were exchanged, compared to its average volume of 457,088. The stock has a 50-day simple moving average of $10.44 and a 200 day simple moving average of $10.09. Kiniksa Pharmaceuticals has a 1-year low of $7.36 and a 1-year high of $15.24.
Get Kiniksa Pharmaceuticals alerts:Institutional Investors Weigh In On Kiniksa Pharmaceuticals
Several large investors have recently added to or reduced their stakes in KNSA. Great Point Partners LLC grew its stake in Kiniksa Pharmaceuticals by 108.3% during the first quarter. Great Point Partners LLC now owns 1,118,067 shares of the company's stock worth $11,114,000 after purchasing an additional 581,329 shares during the period. Goldman Sachs Group Inc. grew its stake in Kiniksa Pharmaceuticals by 61.7% in the first quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company's stock valued at $9,310,000 after acquiring an additional 357,387 shares during the period. Renaissance Technologies LLC acquired a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $3,570,000. Pictet Asset Management SA grew its stake in Kiniksa Pharmaceuticals by 6.4% in the fourth quarter. Pictet Asset Management SA now owns 3,548,649 shares of the company's stock valued at $41,768,000 after acquiring an additional 213,744 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Kiniksa Pharmaceuticals by 126.6% in the first quarter. Dimensional Fund Advisors LP now owns 360,940 shares of the company's stock valued at $3,588,000 after acquiring an additional 201,622 shares during the period. Institutional investors and hedge funds own 42.57% of the company's stock.
Kiniksa Pharmaceuticals Company Profile
(Get Rating)Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
See Also
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- MarketBeat: Week in Review 8/8 – 8/12
- 2 Important Retail Stock Battles to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 1,930,000 shares, a drop of 18.2% from the July 15th total of 2,360,000 shares. Based on an average daily volume of 335,800 shares, the short-interest ratio is currently 5.7 days.
基尼克薩製藥有限公司(納斯達克代碼:KNSA-GET評級)是空頭股數7月份大幅下跌的目標。截至7月31日,空頭股數共有193萬股,與7月15日236萬股的總數相比,下降了18.2%。以日均成交量33.58萬股計算,目前短息比率為5.7天。
Kiniksa Pharmaceuticals Trading Up 2.1 %
Kiniksa製藥公司股價上漲2.1%
NASDAQ KNSA traded up $0.25 during trading hours on Friday, hitting $12.41. 404,852 shares of the company's stock were exchanged, compared to its average volume of 457,088. The stock has a 50-day simple moving average of $10.44 and a 200 day simple moving average of $10.09. Kiniksa Pharmaceuticals has a 1-year low of $7.36 and a 1-year high of $15.24.
上週五,納斯達克KNSA股價上漲0.25美元,至12.41美元。該公司股票成交量為404,852股,而其平均成交量為457,088股。該股的50日簡單移動均線切入位10.44美元,200日簡單移動均線切入位10.09美元。Kiniksa PharmPharmticals的一年低點為7.36美元,一年高位為15.24美元。
Institutional Investors Weigh In On Kiniksa Pharmaceuticals
機構投資者看好Kiniksa製藥公司
Several large investors have recently added to or reduced their stakes in KNSA. Great Point Partners LLC grew its stake in Kiniksa Pharmaceuticals by 108.3% during the first quarter. Great Point Partners LLC now owns 1,118,067 shares of the company's stock worth $11,114,000 after purchasing an additional 581,329 shares during the period. Goldman Sachs Group Inc. grew its stake in Kiniksa Pharmaceuticals by 61.7% in the first quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company's stock valued at $9,310,000 after acquiring an additional 357,387 shares during the period. Renaissance Technologies LLC acquired a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $3,570,000. Pictet Asset Management SA grew its stake in Kiniksa Pharmaceuticals by 6.4% in the fourth quarter. Pictet Asset Management SA now owns 3,548,649 shares of the company's stock valued at $41,768,000 after acquiring an additional 213,744 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Kiniksa Pharmaceuticals by 126.6% in the first quarter. Dimensional Fund Advisors LP now owns 360,940 shares of the company's stock valued at $3,588,000 after acquiring an additional 201,622 shares during the period. Institutional investors and hedge funds own 42.57% of the company's stock.
幾家大型投資者最近增持或減持了KNSA的股份。第一季度,Great Point Partners LLC在Kiniksa製藥公司的持股增加了108.3%。Great Point Partners LLC在此期間又購買了581,329股,現在擁有1,118,067股公司股票,價值11,114,000美元。高盛股份有限公司在第一季度增持了61.7%的基尼克薩製藥股份。高盛股份有限公司在此期間增持了357,387股,目前持有該公司936,604股股票,價值9,310,000美元。復興技術公司在第四季度收購了Kiniksa製藥公司的新股份,價值約為357萬美元。Pictet Asset Management SA在第四季度將其在Kiniksa PharmPharmticals的持股增加了6.4%。Pictet Asset Management SA現在擁有3548,649股該公司的股票,價值41,768,000美元,在此期間又收購了213,744股。最後,Dimension Fund Advisors LP在第一季度將其在Kiniksa製藥公司的持股增加了126.6%。Dimension Fund Advisors LP在此期間額外收購了201,622股,現在擁有360,940股該公司的股票,價值3,588,000美元。機構投資者和對衝基金持有該公司42.57%的股票。
Kiniksa Pharmaceuticals Company Profile
Kiniksa製藥公司簡介
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Kiniksa製藥有限公司是一家生物製藥公司,專注於發現、獲得、開發治療藥物,並將其商業化,用於治療世界各地嚴重未得到滿足的醫療需求的衰弱疾病患者。它的候選產品包括用於治療複發性心包炎的ARCALYST,這是一種炎症性心血管疾病,是一種治療複發性心包炎的藥物;Mavrilimumab,一種完成了治療鉅細胞動脈炎的第二階段臨牀試驗的單抗;Vixarelimab,一種處於2a期臨牀試驗的單抗,用於治療慢性炎症性皮膚疾病結節性瘙癢;以及KPL-404,一種CD40-CD154相互作用的單抗抑制物,一種對B細胞成熟、免疫球蛋白類別轉換和1型免疫反應至關重要的T細胞共刺激信號。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- MarketBeat: Week in Review 8/8 – 8/12
- 2 Important Retail Stock Battles to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於Kiniksa製藥公司(KNSA)的研究報告
- MarketBeat:回顧中的一週2012-8-8
- 值得關注的兩場重要的零售股大戰
- 什麼是WallStreetBets,他們的目標是什麼股票?
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Kiniksa製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Kiniksa製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧